188 related articles for article (PubMed ID: 33872295)
21. Prostate cancer-associated SPOP mutations lead to genomic instability through disruption of the SPOP-HIPK2 axis.
Jin X; Qing S; Li Q; Zhuang H; Shen L; Li J; Qi H; Lin T; Lin Z; Wang J; Cao X; Yang J; Ma Q; Cong L; Xi Y; Fang S; Meng X; Gong Z; Ye M; Wang S; Wang C; Gao K
Nucleic Acids Res; 2021 Jul; 49(12):6788-6803. PubMed ID: 34133717
[TBL] [Abstract][Full Text] [Related]
22. Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation.
Zhang P; Wang D; Zhao Y; Ren S; Gao K; Ye Z; Wang S; Pan CW; Zhu Y; Yan Y; Yang Y; Wu D; He Y; Zhang J; Lu D; Liu X; Yu L; Zhao S; Li Y; Lin D; Wang Y; Wang L; Chen Y; Sun Y; Wang C; Huang H
Nat Med; 2017 Sep; 23(9):1055-1062. PubMed ID: 28805822
[TBL] [Abstract][Full Text] [Related]
23. SPOP suppresses osteosarcoma invasion via PI3K/AKT/NF-κB signaling pathway.
Chen L; Pei H; Lu SJ; Liu ZJ; Yan L; Zhao XM; Hu B; Lu HG
Eur Rev Med Pharmacol Sci; 2018 Feb; 22(3):609-615. PubMed ID: 29461588
[TBL] [Abstract][Full Text] [Related]
24. Monocyte chemoattractant protein-1 modulates invasion and apoptosis of PC-3M prostate cancer cells via regulating expression of VEGF, MMP9 and caspase-3.
Shi CL; Yu CH; Zhang Y; Zhao D; Chang XH; Wang WH
Asian Pac J Cancer Prev; 2011; 12(2):555-9. PubMed ID: 21545229
[TBL] [Abstract][Full Text] [Related]
25. Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover.
Geng C; He B; Xu L; Barbieri CE; Eedunuri VK; Chew SA; Zimmermann M; Bond R; Shou J; Li C; Blattner M; Lonard DM; Demichelis F; Coarfa C; Rubin MA; Zhou P; O'Malley BW; Mitsiades N
Proc Natl Acad Sci U S A; 2013 Apr; 110(17):6997-7002. PubMed ID: 23559371
[TBL] [Abstract][Full Text] [Related]
26. Speckle-type POZ protein is negatively associated with malignancies and inhibits cell proliferation and migration in liver cancer.
Huang Y; Tan N; Jia D; Jing Y; Wang Q; Li Z; Zhang J; Liu L; Li J; Chen Z; He X
Tumour Biol; 2015 Dec; 36(12):9753-61. PubMed ID: 26156804
[TBL] [Abstract][Full Text] [Related]
27. Clinico-pathological significance of the molecular alterations of the SPOP gene in prostate cancer.
García-Flores M; Casanova-Salas I; Rubio-Briones J; Calatrava A; Domínguez-Escrig J; Rubio L; Ramírez-Backhaus M; Fernández-Serra A; García-Casado Z; López-Guerrero JA
Eur J Cancer; 2014 Nov; 50(17):2994-3002. PubMed ID: 25204806
[TBL] [Abstract][Full Text] [Related]
28. CHD1 and SPOP synergistically protect prostate epithelial cells from DNA damage.
Zhu Y; Wen J; Huang G; Mittlesteadt J; Wen X; Lu X
Prostate; 2021 Jan; 81(1):81-88. PubMed ID: 33022763
[TBL] [Abstract][Full Text] [Related]
29. [MTBP regulates migration and invasion of prostate cancer cells
Xiao Z; Chen M; Yang J; Yang C; Lü X; Tian H; Liu C
Nan Fang Yi Ke Da Xue Xue Bao; 2019 Jan; 39(1):6-12. PubMed ID: 30692060
[TBL] [Abstract][Full Text] [Related]
30. [Identification of speckle type BTB/POZ protein mutation regulated key metabolic pathways by cell based proteomics and metabolomics].
Yan M; Liu J; Xia T; Xu G; Piao H
Se Pu; 2019 Aug; 37(8):887-896. PubMed ID: 31642260
[TBL] [Abstract][Full Text] [Related]
31. Prostate cancer-associated mutation in SPOP impairs its ability to target Cdc20 for poly-ubiquitination and degradation.
Wu F; Dai X; Gan W; Wan L; Li M; Mitsiades N; Wei W; Ding Q; Zhang J
Cancer Lett; 2017 Jan; 385():207-214. PubMed ID: 27780719
[TBL] [Abstract][Full Text] [Related]
32. Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics.
Wang H; Barbieri CE; He J; Gao Y; Shi T; Wu C; Schepmoes AA; Fillmore TL; Chae SS; Huang D; Mosquera JM; Qian WJ; Smith RD; Srivastava S; Kagan J; Camp DG; Rodland KD; Rubin MA; Liu T
J Transl Med; 2017 Aug; 15(1):175. PubMed ID: 28810879
[TBL] [Abstract][Full Text] [Related]
33. BTB/POZ domain of speckle-type POZ protein (SPOP) confers proapoptotic function in HeLa cells.
Byun B; Tak H; Joe CO
Biofactors; 2007; 31(3-4):165-9. PubMed ID: 18997279
[TBL] [Abstract][Full Text] [Related]
34. SPOP promotes tumor progression via activation of β-catenin/TCF4 complex in clear cell renal cell carcinoma.
Zhao W; Zhou J; Deng Z; Gao Y; Cheng Y
Int J Oncol; 2016 Sep; 49(3):1001-8. PubMed ID: 27572476
[TBL] [Abstract][Full Text] [Related]
35. Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.
Dai X; Gan W; Li X; Wang S; Zhang W; Huang L; Liu S; Zhong Q; Guo J; Zhang J; Chen T; Shimizu K; Beca F; Blattner M; Vasudevan D; Buckley DL; Qi J; Buser L; Liu P; Inuzuka H; Beck AH; Wang L; Wild PJ; Garraway LA; Rubin MA; Barbieri CE; Wong KK; Muthuswamy SK; Huang J; Chen Y; Bradner JE; Wei W
Nat Med; 2017 Sep; 23(9):1063-1071. PubMed ID: 28805820
[TBL] [Abstract][Full Text] [Related]
36. Prostate Cancer-associated SPOP mutations enhance cancer cell survival and docetaxel resistance by upregulating Caprin1-dependent stress granule assembly.
Shi Q; Zhu Y; Ma J; Chang K; Ding D; Bai Y; Gao K; Zhang P; Mo R; Feng K; Zhao X; Zhang L; Sun H; Jiao D; Chen Y; Sun Y; Zhao SM; Huang H; Li Y; Ren S; Wang C
Mol Cancer; 2019 Nov; 18(1):170. PubMed ID: 31771591
[TBL] [Abstract][Full Text] [Related]
37. Deficiency in SPOP-mediated ubiquitination and degradation of TIAM1 promotes gastric cancer progression.
Liu F; Zhang T; Sun X; Liu Z; Xu W; Dai X; Zhang X
Biochim Biophys Acta Mol Basis Dis; 2024 Mar; 1870(3):167032. PubMed ID: 38246227
[TBL] [Abstract][Full Text] [Related]
38. SPOP Promotes Nanog Destruction to Suppress Stem Cell Traits and Prostate Cancer Progression.
Zhang J; Chen M; Zhu Y; Dai X; Dang F; Ren J; Ren S; Shulga YV; Beca F; Gan W; Wu F; Lin YM; Zhou X; DeCaprio JA; Beck AH; Lu KP; Huang J; Zhao C; Sun Y; Gao X; Pandolfi PP; Wei W
Dev Cell; 2019 Feb; 48(3):329-344.e5. PubMed ID: 30595538
[TBL] [Abstract][Full Text] [Related]
39. Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption.
Lu Y; Cai Z; Xiao G; Keller ET; Mizokami A; Yao Z; Roodman GD; Zhang J
Cancer Res; 2007 Apr; 67(8):3646-53. PubMed ID: 17440076
[TBL] [Abstract][Full Text] [Related]
40. Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion.
Lu Y; Cai Z; Galson DL; Xiao G; Liu Y; George DE; Melhem MF; Yao Z; Zhang J
Prostate; 2006 Sep; 66(12):1311-8. PubMed ID: 16705739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]